AMAG Austria Metall is a holding company, engaged in the production of primary aluminum, as well as cast and rolled aluminum products. The metal division is responsible for the risk management and steering of the metal flows. The casting division recycles aluminum scrap to produce foundry alloys. Its product portfolio covers aluminum materials tailored to customer requirements in the form of ingots, sows and liquid aluminum. The rolling division is responsible for the production and sale of rolled products, and precision cast and rolled plates. The service division include facility management, energy supplies, waste disposal, and purchasing and materials management.

Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Apple designs, manufactures and markets smartphones, personal computers, tablets, wearables and accessories, and sells a variety of related services. The company's products include: iPhone; Mac; iPad; and wearables, home and accessories, which includes AirPods?, Apple TV?, Apple Watch?, Beats? products, HomePod?, iPod touch? and other Apple-branded and third-party accessories. The company's services include: digital content stores and streaming services; AppleCare, which includes AppleCare + (AC+) and the AppleCare Protection Plan; iCloud, which is the company's cloud service; licensing; and other services, which include Apple Arcade?, Apple Card?, Apple News+, and Apple Pay, a cashless payment service.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. The company's main product candidate, AT-007, is a central nervous system, penetrant AR inhibitor (ARI) that the company is developing for the treatment of galactosemia, a rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose. The company's second product candidate, AT-001, is an ARI with systemic exposure and peripheral nerve permeability that the company is developing for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart.

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.

Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. The company is developing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. The company has initiated a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer. The company is developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of women with locally advanced or metastatic ER positive / HER2 negative breast cancer.

Axsome Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders. The company's CNS product candidates includes: AXS-05, which is for the treatment resistant depression and in agitation associated with Alzheimer's disease; AXS-07, which is initially being developed for the acute treatment of migraine; AXS-09, which is being developed for CNS disorders; AXS-12, which is in development for the treatment of narcolepsy; AXS-02, which is being developed for the treatment of knee osteoarthritis and chronic low back pain; and AXS-06, which is being developed for the treatment of osteoarthritis and rheumatoid arthritis.

AXT is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The company's compound substrates combine indium with phosphorous (indium phosphide: InP) or gallium with arsenic (gallium arsenide: GaAs). InP is a semiconductor substrate used in, among others, fiber optic lasers and detectors, passive optical networks, metro and data center connectivity, silicon photonics, infrared motion control and infrared thermal imaging. The company also makes semi-insulating GaAs substrates used in making semiconductor chips in applications such as power amplifiers for wireless devices, transistors and solar cells for drones. In addition, the company sells certain raw materials.

Ballantyne Strong is a holding company. Through its subsidiaries, the company is focused on serving the cinema, retail, financial, advertising and government markets. The company conducts its operations through three operating segments: Strong Cinema, which provides projection screens, technical support services and other related products to the cinema exhibition industry; Convergent, which delivers digital signage solutions and services to various enterprise markets, including retail, banking and healthcare, as well as certain government agencies and Digital-Out-Of-Home advertising network operators; and Strong Outdoor, which provides advertising services and experiential marketing services.

BroadVision develops, markets, and supports enterprise portal applications that enable companies to unify their e-business infrastructure and conduct interactions and transactions with employees, partners, and customers through a personalized self-service model. The company's offerings consist of a framework for personalization and self-service, modular applications and toolsets that customers use to create e-commerce, portal solutions, and enterprise social networking, and collaboration and knowledge management solutions. The company's primary product offerings are software solutions. The company's solutions include Business Agility Suite, Commerce Agility Suite, Clearvale, Clear, QuickSilver and Vmoso.

Cadence is a bank holding company. The company is engaged in commercial lending to middle-market customers and provide a range of commercial loans to middle-market commercial businesses, individuals and business owners. The company's loan portfolio includes commercial and industrial loans, residential real estate loans, commercial real estate loans and other consumer loans. The company also provides its customers a variety of deposit products, including checking accounts, savings accounts, money market accounts and other deposit accounts, through multiple channels, including its network of full-service branches, drive-thru branches, ATMs, ITMs, and its online, mobile and telephone banking platforms.

Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis

cbdMD is a branding and marketing company. Through its CBD Industries LLC subsidiary, the company produces and distributes various cannabidiol (CBD) products, including tinctures, capsules, gummies, bath bombs and topical creams. The company has a line of pet related CBD products under its Paw CBD brand which includes tinctures, treats, and balms. The company's website provides information about CBD quality and existing industry events, as well as United States based customer service. The company tests its hybrid CBD extractions through independent, third-party laboratories. The company's products are available online at www.cbdMD.com and non-affiliated stores.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-infectives for the treatment and prevention of diseases. The company is developing a pipeline of product and development candidates, with a focus on fungal and infections. The company's primary product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of fungal infections. In addition, the company is using its Cloudbreak? platform to develop Antiviral Fc-Conjugates, for the prevention and treatment of influenza and other infections.

CommVault Systems is a provider of data and information management software applications and related services. The company develops, markets and sells a suite of software applications and services, mainly in North America, Europe, Australia and Asia, that provides its customers with data protection solutions. The company also sells appliances that integrate the company's software with hardware. Company also provides its customers with a range of professional and customer support services.

Esperion Therapeutics is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary products, NEXLETOL? tablet and NEXLIZET? tablets, are oral, once-daily, non-statin LDL-C lowering medicines approved in the U.S. for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The U.S. Food and Drug Administration has approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.

Fastenal is engaged in the wholesale distribution of industrial and construction supplies. The company is a distributor of fasteners and related industrial and construction supplies. This includes threaded fasteners, bolts, nuts, screws, studs, and related washers, as well as miscellaneous supplies and hardware, such as pins, machinery keys, concrete anchors, metal framing systems, wire rope, strut, rivets, and related accessories. The company's fastener product line is primarily sold under the Fastenal product name.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Heritage Commerce is a bank holding company. Through its subsidiary, Heritage Bank of Commerce, the company provides a range of commercial banking services to small and medium-sized businesses and their owners, managers and employees. The company's lending activities include commercial, real estate, construction and land development, consumer and Small Business Administration guaranteed loans. The company provides a range of deposit products for business banking and retail markets. The company provides a multitude of other products and services to complement its lending and deposit services. In addition, the company's subsidiary, Bay View Funding, provides factoring financing throughout the United States.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The company's KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. The company also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. The company's clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. The company has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.

Northern Oil and Gas is an independent energy company engaged in the acquisition, exploration, development and production of oil and natural gas properties, primarily in the Bakken and Three Forks formations within the Williston Basin in North Dakota and Montana. The company's primary focus is oil exploration and production through non-operated working interests in wells drilled and completed in spacing units that include its acreage. As a non-operator, the company is able to diversify its investment exposure by participating in a number of gross wells, as well as entering into project areas by partnering with operating partners.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

PNC Financial Services Group is a bank holding company. The company has businesses engaged in retail banking, including residential mortgage, corporate and institutional banking and asset management, providing its products and services nationally. The company's segments are: Retail Banking, which provides deposit, lending, brokerage, insurance services, investment management and cash management products and services; Corporate and Institutional Banking, which provides lending, treasury management, and capital markets-related products and services; Asset Management Group, which provides personal wealth management; and BlackRock, which provides a range of investment and technology services.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Simply Good Foods is a developer, marketer and seller of nutritional foods and snacking products. The company's product portfolio consists primarily of nutrition bars, ready-to-drink shakes, snacks and confectionery products marketed under the Atkins?, SimplyProtein?, and Atkins Endulge? brand names. The Atkins brand approach focuses on a healthy eating approach with reduced levels of refined carbohydrates and sugars and encourages the consumption of lean protein, fiber, fruits, vegetables and healthy fats. Through third-party partnerships, the company provides complementary Atkins branded frozen meals.

Standard AVB Financial is a bank holding company. Through its subsidiary, Standard Bank, PaSB (the Bank), the company provides financial services to individuals, families and businesses. The Bank's business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial business loans, one- to four-family residential mortgage loans, home equity loans and lines of credit and investment securities. The Bank also originates construction loans and consumer loans. The Bank's deposit accounts consist of savings accounts, certificates of deposit and checking accounts.

Taylor Devices is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. These products include: Seismic Dampers, which mitigate the effects of earthquake tremors on structures; Fluidicshoks?, which are shock absorbers for use in the defense, aerospace and commercial industry; Crane and Industrial Buffers, which used for industrial application on cranes, ships, container ships, railroad cars, truck docks, ladle and ingot cars, ore trolleys and car stops; and Self-Adjusting Shock Absorbers, which are designed for high cycle application in heavy industry.

Unifi manufactures and sells recycled and synthetic products made from polyester and nylon primarily to other yarn manufacturers and knitters and weavers that produce yarn and/or fabric for the apparel, hosiery, home furnishings, automotive, industrial and other end-use markets. The company has four segments: Polyester, which sells polyester-based products to other yarn manufacturers, knitters and weavers that produce yarn and/or fabric; Nylon, which sells nylon-based products to knitters and weavers that produce fabric for the apparel and hosiery markets; and Brazil and Asia, which sells polyester-based products to knitters that produce fabric for the apparel markets in South America and in Asia.

Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. The company is engaged in the field of semaphorin 4D (SEMA4D) biology, targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. The company is utilizing its SEMA4D antibody platform to develop its primary product candidate, pepinemab (VX15/2503), an antibody that utilizes mechanisms of action. The company is focused on the development of pepinemab for the treatment of non-small cell lung cancer, Huntington's disease, and Alzheimer's disease.

vTv Therapeutics is a holding company. Through its subsidiaries, the company is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. The company's drug candidate for the treatment of Alzheimer's disease, azeliragon (TTP488), is an orally administered small molecule antagonist targeting the receptor for advanced glycation endproducts. The company's type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor. The company is also developing TTP399 for type 1 diabetes.